Agmatine.

Agmatine is formed by decarboxylation of arginine, so the two sit on one pathway. Agmatine also damps arginase, which leaves more arginine available for nitric oxide synthase.

Arginine is the substrate that arginine decarboxylase turns into agmatine. Agmatine in turn slows arginase, so the arginine pool stays aimed at nitric oxide production.

Citrulline is recycled back to arginine inside endothelial cells, refilling the same pool agmatine protects from arginase. The two act at different points of one route.

Agmatinase converts agmatine to putrescine, the entry point that is then built up into spermidine. Agmatine supply feeds the polyamine pool directly.

Ornithine decarboxylase makes putrescine from ornithine, the same intermediate agmatine yields through agmatinase. Both feed one polyamine pool from two directions.

Magnesium sits in the NMDA channel as a voltage-dependent block while agmatine acts at the polyamine site of the same receptor. Their damping of glutamate signalling overlaps.

Agmatine is formed when arginine decarboxylase removes the carboxyl group from L-arginine, and that enzyme runs on pyridoxal-5-phosphate, the active form of vitamin B6. Adequate B6 status is what keeps the decarboxylation step available, in human tissue and in the bacterial systems used to make supplement-grade material. This is enzymology rather than a co-supplement trial, so read it as mechanistic.

Agmatinase, the enzyme that hydrolyses agmatine into putrescine and urea, is a manganese-dependent hydrolase. Manganese status therefore sits on the clearance side of agmatine handling rather than the production side. No human co-supplementation study defines what that means for a dose, so the relationship is biochemical.

Agmatine interacts with nitric oxide synthase isoforms, while dietary nitrate feeds nitric oxide through the separate nitrate to nitrite reduction route. The two arrive at the same signalling molecule from opposite directions, so the combined effect is not a simple sum. Pre-workout formulas pair them anyway; the pairing is formulation convention more than a measured interaction.

Creatine synthesis draws on arginine and glycine through arginine:glycine amidinotransferase, and agmatine is the decarboxylation product of the same arginine pool. Both therefore compete for and depend on arginine availability. They are routinely blended in the same pre-workout products, which is a formulation fact rather than an efficacy finding.

Agmatine sulfate appears in the same pre-workout matrices as caffeine, where caffeine supplies the stimulant component and agmatine is added for its vasoactive positioning. No trial of the two together defines a combined effect. Read the pairing as formulation convention rather than demonstrated synergy.

Gut and food-fermenting bacteria carry arginine decarboxylase and generate agmatine from dietary arginine; the same enzyme system is what fermentation manufacturers exploit. That makes microbial activity a genuine contributor to agmatine exposure alongside anything swallowed as a capsule. The size of that contribution in people has not been quantified here.

Agmatine binds imidazoline sites and blocks the NMDA receptor channel, targets that sit apart from the GABA-A and GABA-B receptors. Products that combine them are stacking two different neuromodulatory routes rather than reinforcing one. Nothing measured in humans describes the combination.